Resverlogix Corp. (RVX)

0.195
-0.005(-2.50%)
  • Volume:
    23,547
  • Bid/Ask:
    0.195/0.200
  • Day's Range:
    0.190 - 0.200
Earnings results expected today

Resverlogix Corp. will announce its quarterly financial results today. Traders should take this into account as the share price often fluctuates around this time period.

1 / 2

RVX Overview

Prev. Close
0.2
Day's Range
0.19-0.2
Revenue
-
Open
0.2
52 wk Range
0.19-0.82
EPS
-0.102
Volume
23,547
Market Cap
51.57M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
41,829
P/E Ratio
-1.79
Beta
0.338
1-Year Change
-63.21%
Shares Outstanding
264,436,758
Next Earnings Date
Sept 28, 2022
What is your sentiment on Resverlogix Corp.?
or
Market is currently closed. Voting is open during market hours.

Resverlogix Corp. News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Resverlogix Corp. Analysis

Resverlogix Corp. Company Profile

Resverlogix Corp. Company Profile

Employees
0
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA76128M1086
  • CUSIP:76128M108

Resverlogix Corp. is a Canada-based clinical biotechnology company that is focused on improving the lives of patients with chronic illnesses. The Company is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The Company is in the development stage as it is focused on research and development. The Company has not earned any revenue.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Very Strong in Epigenetic drug development, believe very close to definitive results on phase 3 mace trial (RVX-208). All signs IMO are pointing to very positive outcome this year. . Yes  I do have shares!
    1